Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

129 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Murine monoclonal antibodies against RBD of the SARS-CoV-2 spike protein as useful analytical tools for subunit vaccine development and clinical trials.
Blanco OR, Dorta D, Hernández CA, Abreu D, Domínguez AG, Luna Y, Valdivia O, Pérez-Bernal M, Tamayo C, Lemos G, Pasarón IM, Pérez JJ, Benítez L, Bequet-Romero M, Fragas A, Cabrera Y, Pérez ER. Blanco OR, et al. Among authors: hernandez ca. J Immunol Methods. 2022 Jan;500:113195. doi: 10.1016/j.jim.2021.113195. Epub 2021 Nov 26. J Immunol Methods. 2022. PMID: 34843713 Free PMC article.
The Future of Patient Education: AI-Driven Guide for Type 2 Diabetes.
Hernandez CA, Vazquez Gonzalez AE, Polianovskaia A, Amoro Sanchez R, Muyolema Arce V, Mustafa A, Vypritskaya E, Perez Gutierrez O, Bashir M, Eighaei Sedeh A. Hernandez CA, et al. Cureus. 2023 Nov 16;15(11):e48919. doi: 10.7759/cureus.48919. eCollection 2023 Nov. Cureus. 2023. PMID: 38024047 Free PMC article.
Atezolizumab plus bevacizumab versus active surveillance in patients with resected or ablated high-risk hepatocellular carcinoma (IMbrave050): a randomised, open-label, multicentre, phase 3 trial.
Qin S, Chen M, Cheng AL, Kaseb AO, Kudo M, Lee HC, Yopp AC, Zhou J, Wang L, Wen X, Heo J, Tak WY, Nakamura S, Numata K, Uguen T, Hsiehchen D, Cha E, Hack SP, Lian Q, Ma N, Spahn JH, Wang Y, Wu C, Chow PKH; IMbrave050 investigators. Qin S, et al. Lancet. 2023 Nov 18;402(10415):1835-1847. doi: 10.1016/S0140-6736(23)01796-8. Epub 2023 Oct 20. Lancet. 2023. PMID: 37871608 Clinical Trial.
Assessing the risk of a clinically significant infection from a Microneedle Array Patch (MAP) product.
Dul M, Alali M, Ameri M, Burke MD, Craig CM, Creelman BP, Dick L, Donnelly RF, Eakins MN, Frivold C, Forster AH, Gilbert PA, Henke S, Henry S, Hunt D, Lewis H, Maibach HI, Mistilis JJ, Park JH, Prausnitz MR, Robinson DK, Hernandez CAR, Ross C, Shin J, Speaker TJ, Taylor KM, Zehrung D, Birchall JC, Jarrahian C, Coulman SA. Dul M, et al. Among authors: hernandez car. J Control Release. 2023 Sep;361:236-245. doi: 10.1016/j.jconrel.2023.07.001. Epub 2023 Aug 8. J Control Release. 2023. PMID: 37437849 Free article.
Cabozantinib plus Nivolumab and Ipilimumab in Renal-Cell Carcinoma.
Choueiri TK, Powles T, Albiges L, Burotto M, Szczylik C, Zurawski B, Yanez Ruiz E, Maruzzo M, Suarez Zaizar A, Fein LE, Schutz FA, Heng DYC, Wang F, Mataveli F, Chang YL, van Kooten Losio M, Suarez C, Motzer RJ; COSMIC-313 Investigators. Choueiri TK, et al. N Engl J Med. 2023 May 11;388(19):1767-1778. doi: 10.1056/NEJMoa2212851. N Engl J Med. 2023. PMID: 37163623 Free PMC article. Clinical Trial.
129 results